Men Treated for Prostate Cancer Have a Greater Risk for Erectile Dysfunction
Posted on: Monday, 25 October 2004, 13:00 CDT
NEW YORK, Oct. 25 /PRNewswire/ -- Treatment advances are allowing men with prostate cancer to live longer, fuller lives, but most may develop erectile dysfunction, or ED, as a result of prostate cancer treatment. Fortunately, there are treatments for ED that may help.
It's more common than ever for men to be successfully treated for prostate cancer, but we are also seeing a rise in the number who develop ED. There are treatments that may help men with ED related to prostate cancer treatment rediscover their sex lives. One such treatment, which has been shown to be effective in men who develop ED following a certain type of prostate cancer surgery, is Cialis(R), also known as tadalafil.
If you are concerned about prostate cancer or ED or want more information about treatment options for ED, see your doctor. Cialis is not for everyone. If you take nitrates or certain alpha-blockers, do not take Cialis. You and your doctor should determine whether Cialis is right for you and that you are healthy enough for sexual activity.
Producers Note: Cialis is available by prescription only and is not for everyone. If you take nitrates, often used for chest pain (also known as angina), or alpha-blockers (other than Flomax 0.4 mg once daily), prescribed for prostate problems or high blood pressure, do not take Cialis. Such combinations could cause a sudden, unsafe drop in blood pressure. Don't drink alcohol in excess (to a level of intoxication) with Cialis. This combination may increase your chances of getting dizzy or lowering your blood pressure. Cialis does not protect a man or his partner from sexually transmitted diseases, including HIV.
The most common side effects with Cialis were headache and upset stomach. Backache or muscle ache were also reported, sometimes with delayed onset. Most men weren't bothered by the side effects enough to stop taking Cialis. Although a rare occurrence, men who experience an erection for more than four hours (priapism) should seek immediate medical attention. Discuss your medical conditions and medications with your doctor to ensure Cialis is right for you and that you are healthy enough for sexual activity.
Individual results may vary. In clinical trials, Cialis was shown to improve, up to 36 hours after dosing, the ability of men with ED to have a single successful intercourse attempt. Cialis has not been studied for multiple sexual attempts per dose.
Cialis(R) is a registered trademark of Lilly ICOS LLC.
Flomax(R) is a registered trademark.
SOUND BITE:
DR. KEN GOLDBERG
Founder and Medical Director of the Male Health Center in Dallas, Texas
ADDITIONAL RESOURCES: Audio version and more available at
http://www.prnewswire.com/broadcast/20185/consumer.shtml
AUDIO PROVIDED BY: Lilly ICOS LLC.
Audio: Note to Editor - Press Only - includes Audio, MP3 requests,contact information and more available athttp://www.prnewswire.com/broadcast/20185/press.shtml
Lilly ICOS LLC
CONTACT: For story information, please call MultiVu, 1-800-653-5313,ext. 3 or email radio@multivu.com
Web site: http://www.multivu.com/
Source: PRNewswire
Related Articles
- Ferring Pharmaceuticals Announces Trade Name FIRMAGON(R) (degarelix for injection) for Advanced Prostate Cancer Treatment
- Varian Medical Systems to Exhibit Full Spectrum of Prostate Cancer Treatment Technologies at the American Urological Association Meeting in Chicago
- Cancer Treatment Services of Casa Grande, Arizona, Begins Treating Cancer Patients Using Fast, Precise RapidArc(TM) Radiotherapy Technology
- Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments
- Ohio Doctors to See Cancer Treatment in a New Light at Conference in China
- Prostate Cancer Treatment Draws Fire
- Cancer Treatment Targets Not Being Met Scots Hospitals Struggle With Two-Month Limit
- AstraZeneca Takes Over Cancer Treatment Firm
- Pregnancy Hope for Women After Cancer Treatment
- Research and Markets: New Report Examines Hot Topics and Key Issues for Prostrate Cancer Treatment
User Comments (0)

RSS Feeds